

COVAX Allocation status and plan for Q4

- **7 Allocation rounds** have been run to date for a total of **381M doses**, and an additional **145M doses** have been donated through COVAX
- **297M doses have arrived in 141 countries** and territories, as of Sept 21st
- To date, **26 participants** have a coverage **below 10%** (from all sources of supply, COVAX and other) and an additional 23 are below 20%
- In light of this, the **allocation mechanism has been adapted to target participants with low coverage** from all sources of supply

Overview of Allocation Rounds to date and until end of 2021

Allocations to come by end of 2021


Rounds	1	2	3	4	5	6	7	8	9
Publication date/(content)	Feb 21 (Pfizer 1 st wave)	Mar 21 (AZ/SII Feb-May round)	Mar 21 (Pfizer Q2)	Jun 21 (AZ 2 nd doses)	Jul 21 (Pfizer Q3)	Jul 21 (Sinopharm, Sinovac Q3)	Sept 21 (Oct. round ²)	Sept 21 (Nov-Dec. round)	TBD (Nov-Dec. round)
Volume (M doses)	1.2	105	14.1	17.1	72.1	95.6	75.9	High certainty Nov-Dec supply	Residual Nov-Dec supply
Products allocated	Pfizer	AZ, AZ-SII	Pfizer	AZ	Pfizer	Sinopharm, Sinovac	AZ, J&J, Pfizer, Moderna, Sinopharm	AZ, J&J, Pfizer, Moderna	Clover, Novavax, TBC
Methodology	Standard allocation, based on participant population						Participants are selected into rounds based on total coverage (from all sources) to boost lower coverage participants		

1. Depending on EUL of Clover and Novavax vaccines

2. Validated by the IAVG and approved By the WHO DDG on 14 September

Changes made to allocation methodology, with an exceptional round in October for participants with lower coverage from all sources of supply

ILLUSTRATIVE




1. For exceptional/dedicated steps of rounds: list of participants selected for a round will be adjusted by CRD: capping volumes for participants with absorptive capacity information and adding participants who are close to the coverage cut-off mark but have current momentum in administering doses

Zoom - Participants prioritized for R7

Out of 89 AMC and 73
SFPs total in the COVAX
facility

■ SFP Optional ■ SFP Committed ■ AMC92

Participants were prioritised if they had both a low coverage and the
absorption capacity to receive and deploy October volumes¹



1. Participants were prioritised if they had: absorbed more than 75% of doses; no shipments in last month; not featured on the implementation watch list; and/or do not have other sources of doses but under 10% coverage

2. Participants were reviewed below 14.5% total coverage from all sources, incl. participants above original round benchmark of 10% to account for current momentum in administering doses